Our results provide a link between PRKAR2A, type I IFN, gut microbiota, and intestinal inflammation (Fig. S2), suggesting that PRKAR2A inhibition might be a potential therapeutic strategy in treatment for human IBD. This evidence concerns the gene PRKAR2A and inflammatory bowel disease.